Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

OBJECTIVE: Current treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The developmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Ningning, Zhang, Ziheng, Guo, Sanxing, Shen, Shujing, Li, Xingya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244768/
https://www.ncbi.nlm.nih.gov/pubmed/37293311
http://dx.doi.org/10.3389/fmed.2023.1130012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244768/
https://www.ncbi.nlm.nih.gov/pubmed/37293311
http://dx.doi.org/10.3389/fmed.2023.1130012

Ejemplares similares